News

Serious infections are low, but herpes zoster surpasses expectations, review article shows.

Investigators found that habitual glucosamine use was linked to lower risk of cardiovascular disease, coronary heart disease, and stroke.

Previous trials have sought out fracture risk between the therapies over 1 year, and have also found few differences.

Investigators found that patients with undiagnosed severe obstructive sleep apnea were at an increased risk of suffering a postoperative cardiovascular event.

The JAK inhibitor tofacitinib presents a comparably low risk of venous thromboembolism to rheumatoid arthritis patients as do TNFi inhibitors, according to a new study.

Tofacitinib 5 mg or 10 mg twice daily with methotrexate can sustain improvements for 24 months, one study shows.

African American women are disproportionately likely to develop systemic lupus erythematosus, and their disease course is more severe than other demographic groups, says Dr. Edith Williams. In this Q&A, she introduces us to a peer-mentoring program designed to foster self-management.

Patient-doctor narrative matters, says Lisa Rosenbaum, M.D., a cardiologist with Brigham and Women's Hospital in Boston. She shared her insights on patient narratives last month at LUPUS 2019 in San Francisco where she gave the keynote address. Learn more in this Q&A. 

Baricitinib treatment does not increase the risk for cardiovascular problems in patients with rheumatoid arthritis, according to new research.

Rheumatoid arthritis patients taking tofacitinib could face some increased risks for significant cardiovascular events, depending upon their underlying characteristics, according to the results of a new study.

Patients with plaque psoriasis taking apremilast, etanercept, and ustekinumab had a lower rate of serious infections than those who took methotrexate.

Investigators found that female sex, older age, and certain comorbidities were associated with an increased risk of uveitis.

Children affected by juvenile idiopathic arthritis, manifesting as non-systemic polyarthritis, sacroilitis or enthesitis, have a number of therapeutic options available. In this article, we outline the options.

Identifying the type of depression present in an individual with or at-risk for symptomatic knee osteoarthritis can help clinicians best target therapies to reduce pain and disability over time, according to a new study.

Adding acupuncture to topical ibuprofen can provide greater pain relief for patients with osteoarthritis who have chronic knee pain than treating them with only topical ibuprofen, according to recent research.

OARSI 2019: Today―in the era of shared decision making and patient-centered care―patient preferences should be incorporated into clinical practice.

OARSI 2019:  Readmission rates for joint surgery patients are down in Ontario where post-surgery in hospital stays have been shortened.

OARSI 2019:  Osteoarthritis of the hands may be more widespread than previously thought.

OARSI 2019: Phase IIIb clinical trial for the extended release injectable triamcinolone acetonide (Zilretta, Flexion) shows improvement in pain, stiffness and function. 

OARSI 2019:  Using a cane may not foster the growth of medial tibiofemoral bone marrow lesions (BML) in knee osteoarthritis.

OARSI 2019:  Men and women with a mother or sibling who have osteoarthritis, have an increased risk of osteoarthritis in the hips, knees and hands.

OARSI 2019:  Half of opioid prescriptions made today are not aligned with treatment guidelines.

French researchers writing in Arthritis and Rheumatology describe a biomarker that may determine the risk of mortality in patients with dermatomyositis who develop cancer, a common outcome in adults.

Patients with giant cell arteritis treated weekly or bi-weekly with tocilizumab and a prednisone taper experience better outcomes than those treated only with prednisone, a new study shows.

The TNF-inhibitor biosimilar was shown to fare similarly to the marketed therapy in a 52-week efficacy trial.

A new study indicates that a high bone mineral density test of the femoral neck may serve as an indicator of knee and hip osteoarthritis onset.

The expanded indication allows the use of intravenous belimumab (Benlysta) in children as young as 5 years of age.

Patient access to biologic therapies is an issue throughout the European Union where the authors of a review article zero in on “why.” Access issues, they find, have a lot in common with access issues here in the U.S.

Rheumatoid arthritis, psoriasis and psoriatic arthritis patients have consistently low levels of biologic adherence and persistence. How can patient compliance be improved? Lower out-of-pocket costs, utilize specialty pharmacies and improve patient education.

Osteoarthritis patients over age 50 could face a greater risk of mortality after receiving an initial tramadol prescription compared to various commonly prescribed NSAIDS, according to new research.